AstraZeneca takes $100m hit for heart drug failure

13 January 2020 – BBC News

Drugs giant AstraZeneca has undergone a $100m write-down after trials discovered that a heart disease treatment was unsuccessful for treating certain conditions.

The London-listed business is to stop running trials on the drug Epanova after getting the disheartening results.

AstraZeneca said it would carry out a review into the drug’s $533m-value on its balance sheet.

%d bloggers like this: